- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02061722
[PETDE10] Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls With PET. (PEARL-HD)
[PETDE10] Imaging of Phosphodiesterase 10 A (PDE10A) Enzyme Levels in the Living Human Brain of Huntington´s Disease Gene Expansion Carriers and Healthy Controls With Positron Emission Tomography
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark
- The Memory Clinic, Rigshopitalet
-
-
-
-
-
Leiden, Netherlands, K5Q112
- Leiden University Medical Center, Department of Neurology
-
-
-
-
-
Oslo, Norway, 0372 Oslo
- University of Oslo, Nevrologisk poliklinikk
-
-
-
-
-
Lund, Sweden, SE-221 85
- Skane Universitetssjukhus Lund, Neurologiska kliniken
-
Stockholm, Sweden, SE-171 76
- Karolinska University Hospital
-
Stockholm, Sweden, SE-141 86
- Karolinska Universitetssjukhus, Huddinge
-
Stockholm, Sweden, SE-171 76
- KTA Karolinska Trial Alliance
-
Uppsala, Sweden, SE-751 85
- Neurologkliniken Akademiska sjukhuset, ing 85
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Capacity to give full informed consent in writing, and have read and signed the informed consent
- Age 18 to 70 years, inclusive
- HCs: Healthy according to medical history, physical examination, ECG, vital signs, laboratory assessment and MRI, with a body mass index between 19 and 27 (both inclusive)
- HDGECs: Otherwise healthy according to medical history, no co-morbidity of psychotic disorders, physical examination, vital signs and laboratory assessments
- HDGECs:
(A) HD Stage 1 or HD Stage 2: Patients with a clinical diagnosis of HD, defined by the presence of noticeable motor disorder and 40 CAG repeats (HD stage 1: Total Functional Capacity (TFC) 11-13, HD stage 2: TFC 7-10); (B) Pre-manifest: Subjects that are carriers of the mutant Huntingtin gene with ≥40 CAG repeats, a disease burden score ≥ 275 (calculated by the equation ((CAGn-35.5) X age)), and a Total Motor Score (TMS) ≤ 5.
- Able and willing to travel to Stockholm
- Willing to comply with use of adequate contraceptive measures:
Exclusion Criteria:
- Any disease, condition or concomitant medications that significantly compromises the function of the body systems and that, in the opinion of the Investigator might interfere with the conduct of the study or the interpretation
- Regular use of any medication prohibited by this protocol with the exception for Viagra, Levitra and Cialis, which may be temporarily discontinued prior to the PET measurements
- HDGECs: History of other neurological condition (including brain surgery, intracranial haematoma, stroke/cerebrovascular disorders, epilepsy), co-morbidity of psychotic disorders
- HCs: Anamnesis/medical history of neurological conditions (Alzheimer´s disease, dementia, Parkinson´s disease, brain surgery, intracranial haematoma, stroke/cerebrovascular disorders, epilepsy) or psychiatric conditions schizophrenia, depression, bipolar disorder, attention-deficit hyperactivity disorder)
- HCs: Family history of HD
- History of or current alcohol or drug abuse or dependence
- History of anaphylactoid or anaphylactic reactions to any allergen including drugs and contrast media
- Haematological or biochemical parameters that are outside the normal range and are considered clinically significant by the Investigator
- Clinical relevant findings in the 12-lead ECG as determined by the evaluating physician
- Donation of blood (450 mL) within three months prior to Visit 3
- Contraindication to MRI, such as known claustrophobia, presence of metal devises or implants (e.g. pacemaker, vascular- or heart- valves, stents, clips), metal deposited in the body (e.g. bullets or shells), or metal grains in the eyes
- Participating in a clinical trial within the past 3 months
- HCs: previous participation in another PET study
- Positive viral test result for Hepatitis B or C or HIV 1 or 2
- Female subjects: breast-feeding or positive pregnancy test at screening or at Visit 3
- Contraindication for arterial cannulation (by assessment of Allen's test)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: PET Imaging with [18F]MNI-659
All subjects (both HDGECs and HCs) will receive single intravenous doses of the radioligands [11C]raclopride (non-investigational medicinal product [NIMP]) and [18F]MNI-659 (investigational medicinal product [IMP]). The radioligands [11C]raclopride and [18F]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected. The injected radioactivity of [11C]raclopride will be 300 MBq/70 kg of body weight ± 10%. The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%. |
The radioligands [11C]raclopride and [18F]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected. The injected radioactivity of [11C]raclopride will be 300 MBq/70 kg of body weight ± 10%. The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary outcome measure will be the distribution volume (VT) in the striatum (caudate and putamen), globus pallidus, and ventral striatum estimated using kinetic and graphical analysis. Thalamus, cortex and cerebellum will also be examined.
Time Frame: Visit 3: For HD subjects, this will occur within 90 days from the Screening Visit. For Healthy Controls, this will occur within 28 days of Screening visit.
|
Visit 3: For HD subjects, this will occur within 90 days from the Screening Visit. For Healthy Controls, this will occur within 28 days of Screening visit.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Cristina Sampaio, MD, PhD, CHDI Foundation, Inc.
- Principal Investigator: Bernhard Landwehrmeyer, MD, PhD, Ulm University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Genetic Diseases, Inborn
- Basal Ganglia Diseases
- Movement Disorders
- Neurodegenerative Diseases
- Dyskinesias
- Heredodegenerative Disorders, Nervous System
- Dementia
- Cognition Disorders
- Chorea
- Huntington Disease
Other Study ID Numbers
- CHDIKI1201/PET-HD-PDE10A
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Huntington's Disease
-
Massachusetts General HospitalCompletedHuntington's Disease (HD)United States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
SOM Innovation Biotech SACompleted
-
Sanguine BiosciencesHoffmann-La RocheRecruitingHuntington Disease | Huntington's Dementia | Huntington Disease, Late Onset | Huntington; Dementia (Etiology)United States
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
PfizerMedivation, Inc.CompletedAlzheimer's Disease | Huntington's DiseaseUnited States
-
PfizerMedivation, Inc.CompletedHuntington Disease | Alzheimer's DiseaseUnited States
-
Hoffmann-La RocheCompleted
-
PfizerMedivation, Inc.CompletedAlzheimer's Disease | Huntington's DiseaseUnited States
-
PfizerMedivation, Inc.CompletedAlzheimer's Disease | Huntington's DiseaseUnited States
Clinical Trials on PET Imaging with [18F]MNI-659
-
CHDI Foundation, Inc.CompletedHuntington's DiseaseSweden, Denmark, Netherlands, Norway
-
Avid RadiopharmaceuticalsCompletedRadiation Exposure | Diagnostic Agent Adverse ReactionUnited States
-
Nicole HillBlue Earth Diagnostics; Barrow Neurological FoundationRecruitingGrade III or Grade IV GliomaUnited States
-
Aposense Ltd.UnknownHead and Neck Neoplasms | Carcinoma, Non-Small-Cell LungUnited States
-
Vanderbilt-Ingram Cancer CenterCompletedRectal CancerUnited States
-
Alan NicholCompletedCancer (High-grace Glioma)Canada
-
University of Wisconsin, MadisonTerminatedHead and Neck Cancer | Esophageal Cancer | Lung Cancer | Prostate Cancer | CNS Brain MetastasesUnited States
-
University of Alabama at BirminghamRecruitingHER2-positive Breast CancerUnited States
-
Queen Mary University of LondonUnknown
-
Institute for Neurodegenerative DisordersBiogenCompletedMultiple SclerosisUnited States